tag:blogger.com,1999:blog-7866969815563824832024-03-13T16:06:47.512-07:00Physics of Cancer MetastasisNovember 1-2, 2010.
A site for posting meeting information, cancer researcher's top three problems in the understanding and treatment of metastatic cancer and links to their selected papers (1-3).Unknownnoreply@blogger.comBlogger17125tag:blogger.com,1999:blog-786696981556382483.post-13467990056558483272010-10-28T11:33:00.000-07:002010-10-28T14:06:11.060-07:00Geoffrey West, Santa Fe Institute<span style="font-family: Verdana, sans-serif;">Physics Talk </span><span style="font-family: Verdana, sans-serif;">Background Papers:</span><br />
<span style="font-family: Verdana, sans-serif;"></span><br />
<div align="left"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbODcyODQ0ZTctY2RkYi00M2Y0LTg4YTEtNDhiMWUwMzkwMTVm&hl=en&authkey=CPHTsZUE">A quantitative theory of solid tumor growth and vascularization</a></div><div align="left"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbZTM2M2ZkYjktMzFkZC00NmIyLWEyNDQtMTY1MTAxYjk3MGI4&hl=en&authkey=CO-I5D0">Supplimental Material</a></div>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-786696981556382483.post-67206102049462995942010-10-25T12:17:00.000-07:002010-10-28T13:55:51.835-07:00Don Ingber, HarvardCentral Question & Paper: <br />
<ul><li><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbZjJhNzAzZGItMjFmZi00MGQ4LWEwNzQtYWFiYjU5NDhjNjBj&hl=en&authkey=CKLFhMIK">What properties of the embryonic micromenviroment convey its ability to induce cancer differentiation?</a></li>
</ul>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-786696981556382483.post-625202439054658632010-10-06T12:08:00.000-07:002010-10-06T12:08:00.891-07:00Robert Getzenberg (JHU) & Don Coffey (JHU) : Additional Material<span style="color: black; font-family: Verdana, sans-serif;"><strong>These three articles will flow towards the metastatic aspects of the concepts in our discussions.</strong> </span><br />
<br />
<div> </div><span style="color: #1f497d; font-family: Calibri;"><span style="color: black; font-family: Verdana, sans-serif;">We understand that Dr. Michor is attending the meeting but wanted to include one of the papers on which she is an author since it raises what we feel is a very important concept. This manuscript on quasispecies connects chromosome structure to evolution and cancer and introduces some mathematical issues. The recent paper on pattern recognition will provide a link to the physics on this topic. We are sure that Herb Levine will apply his vast experience to this problem. The last of the papers is an old review on the tissue matrix that sets the background <span style="font-family: Verdana, sans-serif;">for the structural aspects of what we will discuss.</span></span><span style="font-family: Verdana, sans-serif;"> </span></span><br />
<br />
<strong><span style="font-family: Verdana, sans-serif;">Background Papers:</span></strong><br />
<ul><li><span style="font-family: Verdana, sans-serif;"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbNDU2ZjFhMDItMzJhYy00ZDFlLWJjY2QtOGJmYTI1ZmVmOGM4&hl=en&authkey=CKCw7tIC">Reaction-Diffusion Model as a Framework for Understanding Biological Pattern Formation</a></span></li>
<li><span style="font-family: Verdana, sans-serif;"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbOWEwOWYzMTYtMzAwMi00NzA5LWFkYjQtZmMwY2RhMjlmOTIw&hl=en&authkey=CJfB2tMC">Genetic instability and the quasispecies model</a></span></li>
<li><span style="font-family: Verdana, sans-serif;"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbZjdjMTYxMmItNDBlMS00ZDhiLWJjZTgtNzMxZTI5MTIyNmEx&hl=en&authkey=CMfS5JsC">The Tissue Matrix: Cell Dynamics and Hormone Action</a></span></li>
</ul>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-786696981556382483.post-5880093000608597152010-10-06T10:40:00.000-07:002010-10-06T10:41:13.235-07:00Chuck Drake, Johns Hopkins University<div class="MsoNormal"><span style="color: #1f497d; font-family: 'Calibri','sans-serif';"><span style="color: black; font-family: Verdana, sans-serif;"><strong>Three Problems:</strong></span></span></div><ul><li><div class="MsoNormal"><span style="color: #1f497d; font-family: 'Calibri','sans-serif';"></span><span style="color: #1f497d; font-family: 'Calibri','sans-serif';"><span style="color: black; font-family: Verdana, sans-serif;">Do cancer cells metastasize as single cells, as clusters of tumor cells, as clusters of tumor and myeloid cells, or as fusions between tumor cells and macrophages?</span></span></div></li>
<li><div class="MsoListParagraph" style="mso-list: l0 level1 lfo1;"><span style="color: #1f497d; font-family: 'Calibri','sans-serif';"><span style="color: black; font-family: Verdana, sans-serif;">What is the relative role of passive (fluid dynamic) versus active processes (diapedesis, extravascation) in the establishment of metastases from tumor cells circulating in the vascular or lymphatic compartments?</span></span></div></li>
<li><div class="MsoListParagraph" style="mso-list: l0 level1 lfo1;"><span style="color: #1f497d; font-family: 'Calibri','sans-serif';"><span style="color: black; font-family: Verdana, sans-serif;">At what stage in the metastatic process are tumor cells most susceptible to immunological intervention?</span> </span></div></li>
</ul><div class="MsoListParagraph" style="mso-list: l0 level1 lfo1;"><span style="color: #1f497d; font-family: 'Calibri','sans-serif';"><span style="color: black; font-family: Verdana, sans-serif;"><strong>Background Papers:</strong></span></span></div><ul><li><span style="font-family: Verdana, sans-serif; font-size: small;"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbMjRjYTY2MWEtOWExNi00MjExLTk3YjctZGI2YWI5ZGFlZjI3&hl=en&authkey=CJafiO8D">Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed?</a></span></li>
<li><div align="left"><span style="font-family: Verdana;"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbMjQ2NjEwOTgtZjM5Yy00N2NmLWJiOTgtZjdlZTRhM2ZiNWIx&hl=en&authkey=CJiuyssN">Integrins in cancer: biological implications and therapeutic opportunities</a></span></div></li>
<li><div align="left"><span style="color: #1f497d; font-family: 'Calibri','sans-serif';"><span style="color: black; font-family: Verdana;"><span style="font-family: ITCSymbolStd-Medium; font-size: x-large;"><span style="font-family: ITCSymbolStd-Medium; font-size: small;"><span style="font-family: ITCSymbolStd-Medium; font-size: x-large;"><span style="font-family: ITCSymbolStd-Medium; font-size: x-large;"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbNjM2YTJmOTAtNjc4Yy00Zjg1LWJmZjQtYWU1MWIzOWVlMWZl&hl=en&authkey=CJ7Vhv8M"><span style="font-size: small;">Fusion of tumour cells with bone </span><span style="font-size: small;">marrow-derived cells: a unifying </span><span style="font-size: small;">explanation for metastasis</span></a></span></span></span></span></span></span></div></li>
<li><div align="left"><span style="color: #1f497d; font-family: 'Calibri','sans-serif';"><span style="color: black; font-family: Verdana;"><span style="font-family: ITCSymbolStd-Medium; font-size: x-large;"><span style="font-family: ITCSymbolStd-Medium; font-size: small;"><span style="font-family: ITCSymbolStd-Medium; font-size: x-large;"><span style="font-family: ITCSymbolStd-Medium; font-size: x-large;"><span style="font-family: Times New Roman; font-size: large;"><span style="font-family: Times New Roman; font-size: large;"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbMDBjZWFjOTAtYWUzMC00MTRmLTk0Y2MtOGYyZmQ4Njk0OTMy&hl=en&authkey=COO1gbIL"><span style="font-family: Verdana, sans-serif; font-size: small;">Circulating Tumor Cell Clusters in the Peripheral Blood of </span><span style="font-family: Verdana, sans-serif; font-size: small;">Colorectal Cancer Patients</span></a></span></span></span></span></span></span></span></span></div></li>
</ul>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-786696981556382483.post-69975023133396246632010-10-06T07:29:00.000-07:002010-10-06T07:29:13.873-07:00Robert Vessella, University of Washington<strong><span style="font-family: Verdana, sans-serif;">Key Challenge:</span></strong><br />
<ul><li><span style="font-family: Verdana, sans-serif;">Development of the technologies that will allow us to isolate viable single metastatic cells and then interrogate those individual cells for molecular signatures and biological behavior. This remains a huge challenge especially in the study of dormancy.</span></li>
</ul><br />
<strong><span style="font-family: Verdana, sans-serif;">Background Papers:</span></strong><br />
<ul><li><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbNTM1ZmU5ZTktNTYxMi00MTU2LWI4MTYtYjkzYzJjYzU4NWY1&hl=en&authkey=CK_857MB"><span style="font-family: Verdana, sans-serif;">Extracellular matrix: A gatekeeper in the transition from dormancy to metastatic growth</span></a> </li>
<li><span style="font-family: Verdana, sans-serif;"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbYWZhMjNmMTItMTliYS00M2Q2LWEyNTEtMmQ4ODU3MTc3MDNk&hl=en&authkey=CImv-tIC">Tumor Dormancy and Metastasis</a></span></li>
</ul>Unknownnoreply@blogger.com1tag:blogger.com,1999:blog-786696981556382483.post-14492878222596490692010-10-05T21:01:00.000-07:002010-10-05T21:16:14.071-07:00Scott Guelcher, Vanderbilt<strong><span style="font-family: Verdana, sans-serif;">Three Questions:</span></strong><br />
<ul><li><span style="font-family: Verdana, sans-serif;">What characteristics unique to the bone microenvironment induce tumor cells to express osteolytic factors after the tumor becomes established in bone?</span></li>
<li><span style="font-family: Verdana, sans-serif;">Over what range of tissue-level mechanical properties can tumor cells respond to the rigidity of the microenvironment?</span></li>
<li><span style="font-family: Verdana, sans-serif;">Are tumor cells genetically programmed to metastasize to bone or are they attracted to the unique characteristics of the bone microenvironment?</span></li>
</ul><br />
<div></div><strong><span style="font-family: Verdana, sans-serif;">Background Papers:</span></strong><br />
<ul><li><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbY2E4MGY3MGEtN2ZkNS00ODM5LTk5YTktY2U3YzY3YjdmYzY3&hl=en&authkey=CNLt9ssI"><span style="font-family: Verdana, sans-serif;">Inhibition of Rho-Associated Kinase Signaling Prevents Breast Cancer Metastasis to Human Bone</span></a></li>
<li><span style="font-family: Verdana, sans-serif;"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbMTZkY2U4MWEtNTE4Yy00Y2EzLWIwMWQtOTFjYjdkY2UwZjdh&hl=en&authkey=CMSZtOEN">Matrix Rigidity Induces Osteolytic Gene Expression of Metastatic Breast <span style="font-family: Verdana, sans-serif;">Cancer Cells</span></a></span></li>
<li><span style="font-family: AdvPSHEL-B; font-size: large;"><span style="font-family: Verdana, sans-serif; font-size: small;"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbYzVlZDhkZjAtM2Q3YS00M2U3LWJmNTktMTUyNzNmMDZmMDE4&hl=en&authkey=CLewvosF">Extracellular Matrix Rigidity Promotes Invadopodia Activity</a></span></span></li>
</ul>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-786696981556382483.post-41108494354820587902010-10-05T20:43:00.000-07:002010-10-05T21:39:39.623-07:00Chris Contag, Stanford<div class="MsoNormal" style="margin: 0in 0in 0pt; mso-layout-grid-align: none; mso-pagination: none;"><span style="color: #666666; font-family: "Verdana", "sans-serif"; mso-bidi-font-family: Verdana;"><strong><span style="font-family: Verdana, sans-serif;">Three Problems:</span></strong></span></div><ul><li><span style="color: #666666; font-family: "Verdana", "sans-serif"; mso-bidi-font-family: Verdana;"><span style="font-family: Verdana, sans-serif;">The small numbers of cells that comprise early metastatic sites make these sites difficult to locate.</span></span></li>
<li><span style="color: #666666; font-family: "Verdana", "sans-serif"; mso-bidi-font-family: Verdana;"><span style="font-family: Verdana, sans-serif;">The nature of metastatic cells is uncertain without clear cell surface markers or other known distinguishing characteristics, and therefore identifying those cells is difficult. Using cell surface markers that are characteristic of late stage disease may not be relevant.</span></span></li>
<li><span style="color: #666666; font-family: "Verdana", "sans-serif"; mso-bidi-font-family: Verdana;"><span style="font-family: Verdana, sans-serif;">The characteristics of a cancer cell the enable it to escape the primary site are not well understood and the markers on such cells have not been described.</span></span></li>
</ul><br />
<div class="MsoNormal" style="margin: 0in 0in 0pt; mso-layout-grid-align: none; mso-pagination: none;"><br />
</div><div class="MsoNormal" style="margin: 0in 0in 0pt; mso-layout-grid-align: none; mso-pagination: none;"><span style="font-family: "Verdana", "sans-serif"; mso-bidi-font-family: Verdana;"><span style="color: #666666;"><span style="font-family: Verdana, sans-serif;"><strong>Background Papers:</strong></span></span></span></div><br />
<ul><li><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbZjgxYWJhOTItNDYzYy00NTg1LWExNDYtMTQ1ZGQzM2RkZDZl&hl=en&authkey=CI2E3LYO"><span style="font-family: Verdana, sans-serif;">Synergistic Antitumor Effects of Immune Cell-Viral Biotherapy</span></a></li>
</ul><br />
<ul><li><div class="MsoNormal" style="margin: 0in 0in 0pt; mso-layout-grid-align: none; mso-pagination: none;"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbNDg1NDA2YzktYzNhYy00MTY0LWFjNWMtNTFmMTUyN2ZjMWI5&hl=en&authkey=CKGUx8ED"><span style="font-family: Verdana, sans-serif;">Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery</span></a></div></li>
</ul><br />
<ul><li><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbNjYxZjcwZDMtZjY3OS00Y2MxLWIxZWItN2U2ZGFjOWZjMjk1&hl=en&authkey=CNiW_LcM"><span style="font-family: Verdana, sans-serif;">Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models.</span></a></li>
</ul>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-786696981556382483.post-88686600610140384312010-10-04T19:23:00.000-07:002010-10-11T08:35:04.234-07:00Lalit Patel, University of Michigan<div class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt; mso-layout-grid-align: none;"><span style="font-family: "Arial", "sans-serif";"><span style="font-family: Verdana, sans-serif;">The progression of prostate cancer is believed to occur in sequential steps. A primary tumor forms, becomes aggressive, disseminates aggressive cells that invade a secondary site, forms a metastasis, the metastases metastasize, and a lethal phenotype emerges. Empirical findings challenge this linear view of disease progression. It has been demonstrated that prostate cancer disseminates to and invades the bone marrow of patients who present with organ-confined early stage primary disease. Although these cells (DTCs) are present at prostatectomy - biochemical evidence of disseminated disease does not present for several years and the cells themselves lack proliferation markers. These findings suggest a latent-phase in which the majority of <i style="mso-bidi-font-style: normal;">Homo sapien</i> bone disseminated prostate cancer cells lack metastatic potential. This raises the following questions:</span></span></div><div class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt; mso-layout-grid-align: none;"><br />
</div><div class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt; mso-layout-grid-align: none;"><span style="font-family: "Arial", "sans-serif";"><span style="font-family: Verdana, sans-serif;">1) Metastogenesis by DTCs:</span></span></div><ul><li><div class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt; mso-layout-grid-align: none;"><span style="font-family: "Arial", "sans-serif";"><span style="font-family: Verdana, sans-serif;">Are bone metastases in <i style="mso-bidi-font-style: normal;">Homo sapiens</i> the slow expansion of rare non-dormant clones or is there a time delayed recurrent secondary-site specific "metastogenic-transformation" that activates skeletal tumor formation by DTCs?</span></span></div></li>
</ul><div class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt; mso-layout-grid-align: none;"><br />
</div><div class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt; mso-layout-grid-align: none;"><span style="font-family: "Arial", "sans-serif";"><span style="font-family: Verdana, sans-serif;">2) Heterogeneity of DTCs:</span></span></div><ul><li><div class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt; mso-layout-grid-align: none;"><span style="font-family: "Arial", "sans-serif";"><span style="font-family: Verdana, sans-serif;">how many molecular-phenotypes of dormancy are there amongst <i style="mso-bidi-font-style: normal;">Homo sapien</i> prostate cancer DTCs?</span></span></div></li>
<li><div class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt; mso-layout-grid-align: none;"><span style="font-family: "Arial", "sans-serif";"><span style="font-family: Verdana, sans-serif;">how many dormancy escape mechanisms are there?</span></span></div></li>
<li><div class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt; mso-layout-grid-align: none;"><span style="font-family: "Arial", "sans-serif";"><span style="font-family: Verdana, sans-serif;">are dormancy escape mechanisms redundant, convergent, or divergent? </span></span></div></li>
<li><div class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt; mso-layout-grid-align: none;"><span style="font-family: "Arial", "sans-serif";"><span style="font-family: Verdana, sans-serif;">is the escape route from dormancy ultimately taken by DTCs predestined by clonal origins or selected for by recurrent secondary transformations at the metastatic site?</span></span></div></li>
</ul><div class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt; mso-layout-grid-align: none;"><br />
</div><div class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt; mso-layout-grid-align: none;"><span style="font-family: "Arial", "sans-serif";"><span style="font-family: Verdana, sans-serif;">3) Seed-Soil relationship of DTC dormancy and the bone microenvironment:</span></span></div><ul><li><div class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt; mso-layout-grid-align: none;"><span style="font-family: "Arial", "sans-serif";"><span style="font-family: Verdana, sans-serif;">is dormancy a byproduct of selection for dormant clones by the metastatic process?</span></span></div></li>
<li><div class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt; mso-layout-grid-align: none;"><span style="font-family: "Arial", "sans-serif";"><span style="font-family: Verdana, sans-serif;">is dormancy induced by the bone marrow microenvironment/metastatic niche?</span></span></div></li>
<li><div class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt; mso-layout-grid-align: none;"><span style="font-family: "Arial", "sans-serif";"><span style="font-family: Verdana, sans-serif;">what microenvironmental cues (molecular, structural, or mechanical) would confer/ablate tumor cell dormancy?</span></span></div></li>
<li><div class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt; mso-layout-grid-align: none;"><span style="font-family: "Arial", "sans-serif";"><span style="font-family: Verdana, sans-serif;">can dormant DTCs “prime-the-soil” through microenvironmental manipulation for future tumor formation? </span></span></div></li>
</ul><div class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt; mso-layout-grid-align: none;"><span style="font-family: "Arial", "sans-serif";"><span style="font-family: Verdana, sans-serif;"></span></span></div><div class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt; mso-layout-grid-align: none;"><b style="mso-bidi-font-weight: normal;"><span style="font-family: "Arial", "sans-serif";"><span style="font-family: Verdana, sans-serif;">Suggested Readings:</span></span></b></div><ul><li><div class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt; mso-layout-grid-align: none;"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbYWQ1ZjZjZTQtYmU1Zi00YjY2LWE3OTYtNWRlZGViNWJiZmQy&hl=en&authkey=COqQzbkH"><span style="font-family: "Arial", "sans-serif";"><span style="font-family: Verdana, sans-serif;">Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer. 2009 Apr;9(4):302-12.</span></span><span style="font-family: "Arial", "sans-serif";"></span></a></div></li>
<li><div class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt; mso-layout-grid-align: none;"><span style="font-family: "Arial", "sans-serif";"><span style="font-family: Verdana, sans-serif;"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbMmIwOWE5MzQtNzQwNC00ZmIxLTgwYzktNTQ4MmQ3ZjBkYzgy&hl=en&authkey=COnxqtwM">Holcomb IN, Grove DI, Kinnunen M, Friedman CL, Gallaher IS, Morgan TM, Sather CL, Delrow JJ, Nelson PS, Lange PH, Ellis WJ, True LD, Young JM, Hsu L, Trask BJ, Vessella RL. Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Res. 2008 Jul 15;68(14):5599-608.</a></span></span></div></li>
<span style="font-family: "Arial", "sans-serif";"><span style="font-family: Verdana, sans-serif;">
<li><div class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt; mso-layout-grid-align: none;"><span style="font-family: "Arial", "sans-serif";"><span style="font-family: Verdana, sans-serif;"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbYWY1MzRkZTItOTExYy00YTk4LWFhN2QtNDFkYjQ3ZDgzNzU0&hl=en&authkey=CPbngMcN">Psaila B, Kaplan RN, Port ER, Lyden D. Priming the 'soil' for breast cancer metastasis: the pre-metastatic niche. Breast Dis. 2006-2007;26:65-74.</a></span></span></div></li>
</span></span><div class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt; mso-layout-grid-align: none;"></div><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgARGw31YlyhQebE4e83a2xzf6IrmkfOeTsWoPaZoMyG2egIYtRzKvZ1-PhIhh6DDvJrKbh3SnfgBeiz7mLFhi_m55rHNVkNRe6HWutvUEdLTewiE4g-lTlzbP1q9d0knbH6H8Wga90EsU9/s1600/Lalit-1.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="186" px="true" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgARGw31YlyhQebE4e83a2xzf6IrmkfOeTsWoPaZoMyG2egIYtRzKvZ1-PhIhh6DDvJrKbh3SnfgBeiz7mLFhi_m55rHNVkNRe6HWutvUEdLTewiE4g-lTlzbP1q9d0knbH6H8Wga90EsU9/s320/Lalit-1.gif" width="320" /></a></div><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhRVcsawgqYxGcTfjEGlMhSQf6CP6BpCOozQkDsHn9BQ6hDZ_YN8UvYNg71zDK__DiDzD8BHfOpKYgHPAqRBLbnAjWQxUE1Oac-3xgZTIAU5B7ym6qLu886rgVwtquKIMpRBH7rXNncZkC5/s1600/lalit-2.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="194" px="true" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhRVcsawgqYxGcTfjEGlMhSQf6CP6BpCOozQkDsHn9BQ6hDZ_YN8UvYNg71zDK__DiDzD8BHfOpKYgHPAqRBLbnAjWQxUE1Oac-3xgZTIAU5B7ym6qLu886rgVwtquKIMpRBH7rXNncZkC5/s320/lalit-2.gif" width="320" /></a></div><div class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt; mso-layout-grid-align: none;"></div></ul>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-786696981556382483.post-76249089481007562582010-09-28T08:46:00.000-07:002010-09-28T09:33:11.576-07:00Evan Keller, University of Michigan<span style="font-family: Verdana, sans-serif;"><strong>Three Problems:</strong></span><br />
<ul><li><span style="font-family: Verdana, sans-serif;">Why is prostate cancer osteoblastic (i.e. most cancers when they spread to bone result in bone resorption (i.e., osteolytic); whereas, prostate cancer results in bone production (i.e. osteoblastic).</span></li>
<li><span style="font-family: Verdana, sans-serif;">Why does prostate cancer preferentially metastasize to bone as opposed to other sites.</span></li>
<li><span style="font-family: Verdana, sans-serif;">How can we successfully treat metastases that are highly heterogenous (i.e within one patient, different metastases have different properties).</span></li>
</ul><span style="font-family: Verdana;"><strong>Background Papers:</strong></span><br />
<ul><li><span style="font-family: Verdana;"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbYTBjNWU2Y2UtZTAwNy00NTIzLWEyNDYtZTM0ZTM2NTg1MWNl&hl=en&authkey=CJLxzvkP">Histopathological Assessment of Prostate Cancer Bone Osteoblastic Metastases</a></span></li>
<li><span style="font-family: Verdana;"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbZTM0MjMxNmQtMGNhZi00M2QyLWE0MzUtYjcwNTc1NTA2MjEx&hl=en&authkey=CM_chN4L">OSTEOBLASTS IN PROSTATE CANCER METASTASIS TO BONE</a></span></li>
</ul>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-786696981556382483.post-2618316108754288532010-09-27T16:09:00.000-07:002010-09-27T16:28:10.791-07:00Robert Getzenberg, Johns Hopkins University<strong><span style="font-family: Verdana, sans-serif;">Three Questions:</span></strong><br />
<ul><li><span style="font-family: Verdana, sans-serif;">Metastatic cancer cells have amplified evolutionary capabilities that allow them to develop resistance to therapeutic approaches.<span style="mso-spacerun: yes;"> </span>This may be enhanced by niches/microenvironments being emptied by “sensitive” populations that do not survive.<span style="mso-spacerun: yes;"> </span>What role do physical and/or structural properties play in the development of resistance and how can modification of these by used to hinder the evolution of cancer?</span></li>
<li><span style="font-family: Verdana, sans-serif;">The concept that cancer cells metastasize as single cells may not be correct.<span style="mso-spacerun: yes;"> </span>Groups of cancers cells along with what appear to be perhaps supporting players have been identified.<span style="mso-spacerun: yes;"> </span>Do cells, other than the tumor cells themselves, “travel” with the cancer cell and aid in the development of metastatic sites?<span style="mso-spacerun: yes;"> </span>If so, are they from the site of origin or are they recruited from other sources?<span style="mso-spacerun: yes;"> </span>Can we image these?</span></li>
<li><span style="font-family: Verdana, sans-serif;">It appears that heat can be used to increase the sensitivity cancer cells to other forms of therapy and that the price that the cancer cells pays for being so able to develop resistance to therapy is a sensitivity to microenvironmental stresses.<span style="mso-spacerun: yes;"> </span>What physical properties of the cells have been altered that creates this sensitivity to stresses?<span style="mso-spacerun: yes;"> </span></span></li>
</ul>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-786696981556382483.post-57220483796739788092010-09-27T16:00:00.001-07:002010-09-27T16:04:25.802-07:00Don Coffey, Johns Hopkins University<strong>Central Question:</strong><br />
<blockquote>Why is there so much variation (heterogeneity) within solid tumors in relation to cell structure and function and how might this relate to energy, information transfer, and self-organization?</blockquote>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-786696981556382483.post-75824003335005905142010-09-23T15:15:00.000-07:002010-09-23T15:15:38.563-07:00Gary Stein, University of Massachusetts<div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-family: Verdana, sans-serif;">Three Problems:</span></div><ul><li><div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-family: Verdana, sans-serif;">Epigenetic control in tumorigenesis, tumor progression and metastasis <sup>1</sup></span></div></li>
<li><div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-family: Verdana, sans-serif;">Nuclear microenvironments in biological control and cancer <sup>2</sup></span></div></li>
<li><div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-family: Verdana, sans-serif;">Cell adhesion and motility in tumor progression <sup>3</sup></span></div></li>
</ul><div class="MsoNormal" style="margin: 0in 0in 0pt;"><br />
</div><div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-family: Verdana, sans-serif;">References:</span></div><div class="MsoNormal" style="margin: 0in 0in 0pt;"><br />
</div><div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-family: Verdana, sans-serif;"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbYzczNzI4OGYtMzg4YS00NzZkLTkyYWItOGNkMzRiYmQ1Zjgy&hl=en&authkey=CIGy0s8F"><sup>1</sup>Zaidi SK, Young DW, Montecino M, Lian JB, van Wijnen AJ, Stein JL, Stein GS. (2010) Mitotic bookmarking of genes: a novel dimension to epigenetic control. Nature Reviews Genetics <span class="src1">Aug;11(8):583-9. Epub 2010 Jul 13.</span></a></span></div><div class="MsoNormal" style="margin: 0in 0in 0pt;"><br />
</div><div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-family: Verdana, sans-serif;"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbODkxYWUxZWMtM2UwZS00NGZmLThiYTQtNGU2NjY4OTY2ZDI0&hl=en&authkey=CJq6te8P"><sup>2</sup>Zaidi SK, Young DW, Javed A, Pratap J, Montecino M, van Wijnen AJ, Lian JB, Stein JL, Stein GS<span style="mso-spacerun: yes;"> </span>(2007) Nuclear microenvironments in biological control and cancer.<span style="mso-spacerun: yes;"> </span>Nature Reviews Cancer, 7:454-463.</a></span></div><div class="MsoNormal" style="margin: 0in 0in 0pt;"><br />
</div><div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-family: Verdana, sans-serif;"><a href="http://www.blogger.com/goog_1514908353"><sup>3</sup>Altieri DC, Languino LR, Lian JB, Stein JL, Leav I, van Wijnen AJ, Jiang Z, Stein GS. </a></span><span style="font-family: Verdana, sans-serif;"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbMzI4YzQyODgtOWEzYi00YjY2LThhNGYtOWYzZWRkNTQ4NWI3&hl=en&authkey=CPidspEL">Article.<span style="mso-spacerun: yes;"> </span>(2009) Prostate cancer regulatory networks. J Cell Biochem. Aug 1;107(5):845-52.</a> </span></div>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-786696981556382483.post-32817182507331993642010-09-23T15:03:00.000-07:002010-09-23T15:03:13.911-07:00Lance Munn, Harvard<span style="font-family: Verdana, sans-serif;">Three Questions:</span><br />
<ul><li><span style="font-family: Verdana, sans-serif;">Can we identify patients who would benefit from treatment aimed at preventing metastasis or further metastasis? </span></li>
<li><span style="font-family: Verdana, sans-serif;">How does the accumulation of compressive stress affect invasion and metastasis?</span></li>
<li><span style="font-family: Verdana, sans-serif;">What role do host stromal cells or cancer cell cooperation play in invasion and metastasis?</span></li>
</ul><br />
<div> </div><span style="font-family: Verdana, sans-serif;">Background Papers:</span><br />
<ul><li><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbZDg2N2ZhYmQtZWJlOS00M2NkLWFiZDItNDY2MjUxNTlhNTc5&hl=en&authkey=CODgvLAI"><span style="font-family: Verdana, sans-serif; font-size: small;">Intravascular origin of metastasis from the proliferation of </span><span style="font-family: Verdana, sans-serif; font-size: small;">endothelium-attached tumor cells: a new model for metastasis</span></a></li>
<li><div align="left"><span style="font-family: Verdana, sans-serif;"><span style="font-size: small;"><span style="color: #231f20; font-family: Shaker2Lancet-Bold; font-size: large;"><span style="color: #231f20; font-family: Shaker2Lancet-Bold; font-size: large;"><span style="color: #231f20; font-family: Shaker2Lancet-Bold; font-size: large;"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbNDdlYjE0YzgtMTdjZC00MDU1LWI1ZmQtMTEyYTY4YTJlMTc5&hl=en&authkey=COXnnO4L"><span style="font-family: Verdana, sans-serif; font-size: small;">Active versus passive mechanisms in metastasis: do cancer </span><span style="font-family: Verdana, sans-serif; font-size: small;">cells crawl into vessels, or are they pushed?</span></a></span></span></span></span></span></div></li>
<li><div align="left"><span style="font-family: Verdana, sans-serif;"><span style="font-size: small;"><span style="color: #231f20; font-family: Shaker2Lancet-Bold; font-size: large;"><span style="color: #231f20; font-family: Shaker2Lancet-Bold; font-size: large;"><span style="color: #231f20; font-family: Shaker2Lancet-Bold; font-size: large;"><span style="font-family: Helvetica-Bold; font-size: medium;"><span style="font-family: Helvetica-Bold; font-size: medium;"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbZjljNWJiMTMtNjYwZS00Y2VmLThkMmItMDE0NTUwODY4MjNl&hl=en&authkey=CLCPj8YN"><span style="font-family: Verdana, sans-serif; font-size: small;">Mechanisms of c</span><span style="font-family: Verdana, sans-serif; font-size: small;">ollective cell migration </span><span style="font-family: Verdana, sans-serif; font-size: small;">at a glance</span></a></span></span></span></span></span></span></span></div></li>
</ul>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-786696981556382483.post-88883724317254418132010-09-20T09:11:00.000-07:002010-09-20T09:27:31.220-07:00Yibin Kang, Princeton<div style="color: #666666; font-family: Verdana;"></div><span class="664200218-19092010"><span style="color: black; font-family: Verdana, sans-serif;">Questions</span></span><br />
<ul><li><span class="664200218-19092010"><span style="color: black; font-family: Verdana, sans-serif;">Do tumor cells behave differently as solitary cells (disseminated tumor cells or micrometastasis) and as overt metastasis. Is a critical mass required for tumor cells to manifest their full malignant potential and how does this relates to metastatic dormancy?</span></span></li>
<li><span class="664200218-19092010"><span style="color: black; font-family: Verdana, sans-serif;">Is there a fitness cost for tumor cells to overcome different hurdles of metastasis? For example, when tumor cells undergo epithelial mesenchymal transition to invade and migrate, are they more susceptible to certain drugs. </span></span></li>
<li><span class="664200218-19092010"><span style="color: black; font-family: Verdana, sans-serif;">What are the key molecular pathways that mediate tumor-stromal interactions in metastasis? How to we effectively deliver therapeutics to disseminated tumor cells or micrometastasis to prevent distant recurrence?</span></span><span class="664200218-19092010"><span style="color: black; font-family: Verdana, sans-serif;"></span></span></li>
</ul><span class="664200218-19092010"><span style="color: black; font-family: Verdana, sans-serif;">Background Papers</span></span><br />
<ul><li><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbYzQ5N2YyYWItYWI4OC00ZGM0LWExODgtYjRkOWZiZjQ2OGY4&hl=en&authkey=CMi0q5gP"><span style="font-family: Verdana, sans-serif; font-size: small;">ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic </span><span style="font-family: Verdana, sans-serif; font-size: small;">signaling cascade for bone metastasis</span></a><span style="font-family: Verdana, sans-serif; font-size: small;"><span style="font-family: HelveticaNeue-Bold; font-size: large;"><span style="font-family: HelveticaNeue-Bold; font-size: large;"></span></span></span></li>
<li><span style="font-family: Verdana, sans-serif; font-size: small;"><span style="font-family: HelveticaNeue-Bold; font-size: large;"><span style="font-family: HelveticaNeue-Bold; font-size: large;"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbZDVmZTk2NTQtMTcyYS00MGQ0LWFhM2ItYjVlYTkwOWNhYjAx&hl=en&authkey=CMCVt4cH"><span style="font-family: Verdana, sans-serif; font-size: small;">A multigenic program mediating breast cancer metastasis </span><span style="font-family: Verdana, sans-serif; font-size: small;">to bone</span></a></span></span></span></li>
<li><span style="font-family: Verdana; font-size: small;"><span style="font-family: Verdana, sans-serif;"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbMzhmODUyNzktY2IwZS00MzQwLWEyNjEtMGMyNzcwNWQ4Nzhi&hl=en&authkey=CPHCz9kP">Imaging transforming growth factor-b <span style="font-family: AdvTgl; font-size: x-large;"><span style="font-family: AdvTgl; font-size: x-large;"><span style="font-size: small;">signaling dynamics and therapeutic response in breast cancer bone metastasis</span></span></span></a></span></span></li>
</ul>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-786696981556382483.post-37330561602122321582010-09-17T07:36:00.000-07:002010-09-20T09:25:51.216-07:00Ken Pienta, University of Michigan<span style="font-family: Verdana, sans-serif;">Three questions:</span><br />
<ul><li><span style="font-family: Verdana, sans-serif;">How efficient is the metastatic process? What are the qualities of a cancer cell that is a successful metastatic seed?</span></li>
<li><span style="font-family: Verdana, sans-serif;">How do the physical qualities of the target organ affect the establishment of a metastasis?</span></li>
<li><span style="font-family: Verdana, sans-serif;">How do cells survive the turbulence of the circulation?</span></li>
</ul><span style="font-family: Times New Roman;"></span><br />
<div align="left"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgtUX6nNZcw0PXCFctUU-26YGBWatWh6RADzUD-FP_o1ZiJbIkqlLqAist0m822JgkUlfF9BXZ6GLev1o0C-fGvIbI3clV9qnRLBOHLBgyGNY1Q6UZkaehysXxleiY7ct8vDdP2Qj_kdv9b/s1600/Slide1.JPG" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><strong><img border="0" qx="true" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgtUX6nNZcw0PXCFctUU-26YGBWatWh6RADzUD-FP_o1ZiJbIkqlLqAist0m822JgkUlfF9BXZ6GLev1o0C-fGvIbI3clV9qnRLBOHLBgyGNY1Q6UZkaehysXxleiY7ct8vDdP2Qj_kdv9b/s320/Slide1.JPG" /></strong></a></div><div align="left"><br />
</div><div align="left"><span style="font-family: Verdana, sans-serif;">Background Papers:</span></div><div align="left"><ul><li><span style="font-family: Verdana, sans-serif;"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbMmM5NzBkMDktMzNlOS00YTdkLWEyNjgtN2IyZTJiOTVmNmFj&hl=en&authkey=CPypjvYI">The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy</a></span><span style="font-family: Verdana, sans-serif;"><span style="color: #231f20; font-family: Minion-Regular; font-size: large;"><span style="color: #231f20; font-family: Minion-Regular; font-size: large;"><span style="color: #231f20; font-family: Minion-Regular; font-size: large;"><span style="font-family: Verdana, sans-serif; font-size: small;"></span></span></span></span></span></li>
<li><span style="font-family: Verdana, sans-serif;"><span style="color: #231f20; font-family: Minion-Regular; font-size: large;"><span style="color: #231f20; font-family: Minion-Regular; font-size: large;"><span style="color: #231f20; font-family: Minion-Regular; font-size: large;"><span style="font-family: Verdana, sans-serif; font-size: small;"><a href="https://docs.google.com/fileview?id=0B9eDULFfT0lbOTNmYjFhYzMtYjFlMC00Njk3LTkzMmYtNmQ1ZTE1Njk5NDk2&hl=en&authkey=CLz8lJwD">Pathogenesis and Treatment of Prostate Cancer Bone Metastases: Targeting the Lethal Phenotype</a></span></span></span></span></span></li>
</ul></div>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-786696981556382483.post-79172095424813241172010-09-16T15:44:00.000-07:002010-09-24T07:51:28.571-07:00Meeting Logistics<span style="font-family: "Trebuchet MS", sans-serif;"><strong>Dates:</strong> </span><br />
<span style="font-family: "Trebuchet MS", sans-serif;">November 1-2, 2010 <strong>(October 31st, registration and opening discussion with refreshments in the evening for those available, time 6-8pm.)</strong></span><br />
<span style="font-family: "Trebuchet MS", sans-serif;"><br />
</span><br />
<span style="font-family: "Trebuchet MS", sans-serif;"><strong>Location:</strong> </span><br />
<a href="http://www1.hilton.com/en_US/hi/hotel/DCAVAHF-Hilton-Arlington-Virginia/index.do"><span style="font-family: "Trebuchet MS", sans-serif;">Hilton-Arlington</span></a><span style="font-family: "Trebuchet MS", sans-serif;">, 950 North Stafford Street, Arlington, VA 22203 </span><br />
<span style="font-family: "Trebuchet MS", sans-serif;"><strong>Note: Reservations and hotel payment will be made via meeting coordinator. Please forward your reservation dates to <a href="mailto:sara.bradley@comcast.net">Sara</a>. </strong></span><br />
<br />
<span style="font-family: "Trebuchet MS", sans-serif; font-size: small;"><strong>Directions & Transportation:</strong> <a href="http://www1.hilton.com/en_US/hi/hotel/DCAVAHF-Hilton-Arlington-Virginia/directions.do">Link</a></span><br />
<br />
<strong><span style="font-family: "Trebuchet MS", sans-serif;">Travel:</span></strong><br />
<span style="font-family: "Trebuchet MS", sans-serif;">Please make your own travel arrangements. Attendee's are encouraged to make air/ground transportation reservations as early as possible to capitalize on reduced fares. Currently, the organizers are budgeted for air travel at the following RT rates: West coast ~$700; Mid-West, ~$600; and East Coast, ~$300. Air/ground transportation will be reimbursed after the meeting by UCSD. You will be given detailed instructions on how to submit your travel reimbursements at or shortly after the meeting. </span><br />
<br />
<span style="font-family: "Trebuchet MS", sans-serif;">Please be aware of the following restrictions: UC will reimburse you for economy/coach class air travel (or the equivalent of an economy/coach fare if you decide to fly business/first class) and original receipts are required. For those living within driving distance, you may receive a mileage per diem (and parking fee reimbursement) if you use your personal vehicle. Taxis, shuttles and train expenses (within reasonable limits) will also be reimbursed.</span><br />
<br />
<span style="font-family: "Trebuchet MS", sans-serif;">Please forward your itinerary and ticket price to the meeting coordinator, Sara Bradley at <span class="Object" id="OBJ_PREFIX_DWT1887"><a href="mailto:sara.bradley@comcast.net" target="_blank">sara.bradley@comcast.net</a></span>. </span><br />
<br />
<strong><span style="font-family: "Trebuchet MS", sans-serif;">Agenda:</span></strong><br />
<span style="font-family: "Trebuchet MS", sans-serif;"><u>Sunday, October 31st:</u> registration and opening discussion with refreshments in the evening for those available, time 6-8pm.</span><br />
<span style="font-family: Trebuchet MS;"><u>Monday, November 1:</u> t</span><span style="font-family: "Trebuchet MS", sans-serif;">alks and discussion will run the full day on Monday, dinner to follow.</span><br />
<span style="font-family: "Trebuchet MS", sans-serif;"><u>Tuesday, November 2:</u> talks and discussion will run to approximately 3pm. </span><br />
<span style="font-family: "Trebuchet MS", sans-serif;">Detailed agenda tba.</span><br />
<span style="font-family: "Trebuchet MS", sans-serif;"><br />
</span><br />
<strong><span style="font-family: "Trebuchet MS", sans-serif;">Meeting Coordinator:</span></strong><br />
<a href="mailto:sara.bradley@comcast.net"><span style="font-family: "Trebuchet MS", sans-serif;">Sara Bradley</span></a>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-786696981556382483.post-61780517280205645982010-09-15T10:49:00.000-07:002010-10-15T10:51:20.979-07:00Physics of Cancer Metastasis<a href="http://biologyphysics.blogspot.com/">Physics of Cancer Metastasis</a>Unknownnoreply@blogger.com1